This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Glenmark, Merck win reversal of class certification in Zetia pay-for-delay case

( August 4, 2021, 20:10 GMT | Official Statement) -- MLex Summary: Glenmark and Merck have gotten class certification reversed in direct purchasers’ antitrust case alleging an illegal pay-for-delay agreement over the cholesterol drug Zetia. The US Court of Appeals for the Fourth Circuit determined that because the lower court's numerosity analysis "improperly looked to the impracticability of individual suits rather than joinder, we are compelled to conclude that legal error infected the court’s class-certification decision."See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections